Cariprazine Shows High Tolerability and Completion Rates in Major Depressive Disorder Patients
Cariprazine, approved by the FDA as an adjunctive treatment for MDD, has demonstrated positive outcomes in various trials. The analysis focused on its safety profile, leveraging data from five randomized, double-blind, placebo-controlled trials involving patients with inadequate responses to monotherapy antidepressant treatment. A recent pooled analysis of phase 3 trials has shed light on the […]